ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
1 . An isolated monoclonal antibody, or antigen binding fragment thereof, that binds epidermal growth factor receptor (EGFR), wherein the antibody comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 2.
2 . An isolated monoclonal antibody, or antigen binding fragment thereof, that binds epidermal growth factor receptor (EGFR), wherein the antibody comprises heavy and light chain variable regions, wherein the light chain variable region comprises the sequence set forth in SEQ ID NO: 13.
3 . An isolated monoclonal antibody, or antigen binding fragment thereof, that binds epidermal growth factor receptor (EGFR), wherein the antibody comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 2 and the light chain variable regions comprises the sequence set forth in SEQ ID NO: 13.
4 . The monoclonal antibody of claim 1 , wherein the antibody is a human antibody.
5 . The monoclonal antibody of claim 1 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies.
6 . The monoclonal antibody of claim 1 , wherein the monoclonal antibody is an IgG1 isotype antibody.
7 . The monoclonal antibody of claim 2 , wherein the antibody is a human antibody.
8 . The monoclonal antibody of claim 2 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies.
9 . The monoclonal antibody of claim 2 , wherein the monoclonal antibody is an IgG1 isotype antibody.
10 . The monoclonal antibody of claim 3 , wherein the antibody is a human antibody.
11 . The monoclonal antibody of claim 3 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies.
12 . The monoclonal antibody of claim 3 , wherein the monoclonal antibody is an IgG1 isotype antibody.
13 . A composition comprising the monoclonal antibody of any one of claims 1 - 12 and a pharmaceutically acceptable carrier.